Clinical tumor lysis syndrome associated with elranatamab in relapsed multiple myeloma: a case report
Introduction: Multiple Myeloma (MM) is currently an incurable disease, with constant relapses and the need for multiple lines of treatment. Immune therapies, which include bispecific antibodies such as elranatamab, are a new option for the treatment of patients with relapsed/refractory MM (R/R MM),...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | Artículo revista |
| Lenguaje: | Inglés |
| Publicado: |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología
2026
|
| Materias: | |
| Acceso en línea: | https://revistas.unc.edu.ar/index.php/med/article/view/49234 |
| Aporte de: |
| Sumario: | Introduction: Multiple Myeloma (MM) is currently an incurable disease, with constant relapses and the need for multiple lines of treatment. Immune therapies, which include bispecific antibodies such as elranatamab, are a new option for the treatment of patients with relapsed/refractory MM (R/R MM), with high effectiveness, but not free of adverse reactions. Tumor lysis syndrome (TLS) is a rare complication of MM treatment and has not been reported after application of elranatamab.
Case Presentation: We report the case of a man with R/R MM who presented TLS after application of the first dose of elranatamab. The TLS resolved after supportive measures without subsequent recurrence.
Conclusion: TLS is an uncommon complication of MM treatment and could be triggered by bispecific antibodies. |
|---|